Background/Objectives:Radiotherapy is a cornerstone in the treatment of breast cancer, yet its use is frequently accompanied by skin toxicities that vary in severity and timing among patients. The objective of this meta-analysis is to systematically evaluate the pooled impact of genetic variations on the risk and severity of acute and late skin side effects from radiotherapy in breast cancer patients.Materials and Methods:A systematic literature search was conducted across PubMed, Embase, and Scopus to identify studies published between 2014 and 2024 that examined associations between genetic polymorphisms and radiotherapy-induced skin toxicity. Studies were selected based on predefined inclusion and exclusion criteria, and data were synthesized using a random-effects meta-analysis model. The risk of bias was evaluated using the ROBINS-I tool, and publication bias was assessed through funnel plots and Egger’s test.Results:A total of 11 studies involving breast cancer patients were included, identifying associations between various gene polymorphisms and skin toxicity. The pooled analysis revealed that patients with specific genetic variants had a 53% increased risk of acute skin side effects and a 44% increased risk of late effects. Notable implicated genes included XRCC2, IFNG, ATM, TGFB1, and PER3. Significant heterogeneity and publication bias were noted across studies, warranting cautious interpretation.Conclusions:This meta-analysis highlights the role of genetic variation in predicting radiotherapy-induced skin toxicity in breast cancer patients. These findings support the future development of predictive biomarkers and personalized radiotherapy strategies to minimize treatment-related toxicity.
背景/目的：放射治疗是乳腺癌治疗的基石，但其应用常伴随皮肤毒性反应，且其严重程度和发生时间在患者间存在差异。本荟萃分析旨在系统评估遗传变异对乳腺癌患者放疗所致急性和晚期皮肤副作用风险及严重程度的综合影响。 材料与方法：通过系统检索PubMed、Embase和Scopus数据库，纳入2014年至2024年间发表的探讨基因多态性与放疗所致皮肤毒性关联的研究。研究根据预设的纳入与排除标准进行筛选，并采用随机效应荟萃分析模型进行数据合成。使用ROBINS-I工具评估偏倚风险，通过漏斗图和Egger检验评估发表偏倚。 结果：共纳入11项涉及乳腺癌患者的研究，识别出多种基因多态性与皮肤毒性的关联。汇总分析显示，携带特定遗传变异的患者发生急性皮肤副作用的风险增加53%，发生晚期副作用的风险增加44%。涉及的主要基因包括XRCC2、IFNG、ATM、TGFB1和PER3。研究间存在显著的异质性和发表偏倚，需谨慎解读结果。 结论：本荟萃分析强调了遗传变异在预测乳腺癌患者放疗所致皮肤毒性中的作用。这些发现为未来开发预测性生物标志物和个体化放疗策略以降低治疗相关毒性提供了支持。
肿瘤(癌症)患者之家